Opus Genetics (IRD) Share-based Compensation Growth (3y) (2013 - 2026)
Powered by 
Analysis
Opus Genetics (IRD) Share-based Compensation Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.91% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 17.49% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.95% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.55% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 30.98% |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | -25.80% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.80% |
| Mar 31, 2026 | -81.90% |
| Dec 31, 2025 | 22.22% |
| Sep 30, 2025 | 290.84% |
| Jun 30, 2025 | 304.41% |
| Mar 31, 2025 | 124.06% |
| Dec 31, 2024 | 18.40% |
| Sep 30, 2024 | 116.46% |
| Jun 30, 2024 | 120.48% |
| Mar 31, 2024 | 41.29% |
| Dec 31, 2023 | -55.17% |
| Sep 30, 2023 | 77.92% |
| Jun 30, 2023 | 121.73% |
| Mar 31, 2023 | 855.29% |
| Dec 31, 2022 | 98.43% |
| Sep 30, 2022 | 30.93% |
| Jun 30, 2022 | 23.14% |
| Mar 31, 2022 | 90.09% |
| Dec 31, 2021 | 7.73% |
| Sep 30, 2021 | -43.13% |